BIIB Biogen Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BIIB

Price (delayed)

$250.52

Market cap

$37.03B

P/E Ratio

106.15

Dividend/share

N/A

EPS

$2.36

Enterprise value

$43.53B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 43

Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with ...

Highlights
The equity has grown by 3.9% YoY
The gross profit is up by 2.6% since the previous quarter
Biogen's debt has increased by 18% YoY but it has decreased by 7% from the previous quarter
The P/E is 148% above the last 4 quarters average of 43.3
The EPS has plunged by 79% YoY and by 58% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.biogen.com
Peers: AMGN GILD PFE ABBV

Key stats

What are the main financial stats of BIIB

BIIB stock price

How has the Biogen stock price performed over time
Intraday
-1.14%
1 week
2.7%
1 month
9.2%
1 year
55.14%
YTD
42.35%
QTD
10.91%

Financial performance

How have Biogen's revenue and profit performed over time
Revenue
$10.3B
Gross profit
$7.62B
Operating income
$445.1M
Net income
$347.5M
Gross margin
74%
Net margin
3.4%
Biogen's net margin has plunged by 79% YoY and by 59% from the previous quarter
Biogen's net income has shrunk by 78% YoY and by 58% QoQ
Biogen's operating margin has plunged by 77% YoY and by 57% from the previous quarter
BIIB's operating income has dropped by 77% year-on-year and by 56% since the previous quarter

Price vs fundamentals

How does BIIB's price correlate with its fundamentals

Growth

What is Biogen's growth rate over time

Valuation

What is Biogen stock price valuation
BIIB P/E details
P/E
106.15
P/B
1.96
P/S
3.6
EV/EBIT
97.8
EV/EBITDA
32.7
EV/Sales
4.23
The P/E is 148% above the last 4 quarters average of 43.3
The EPS has plunged by 79% YoY and by 58% from the previous quarter
BIIB's price to book (P/B) is 24% higher than its last 4 quarters average of 1.6 but 6% lower than its 5-year quarterly average of 2.1
The equity has grown by 3.9% YoY
The stock's price to sales (P/S) is 26% more than its last 4 quarters average of 2.9 and 17% more than its 5-year quarterly average of 3.1
Biogen's revenue has increased by 2.7% from the previous quarter and by 2.3% YoY

Efficiency

How efficient is Biogen business performance
Biogen's return on assets has shrunk by 81% YoY and by 61% QoQ
The ROIC has plunged by 81% YoY and by 58% from the previous quarter
The ROE has plunged by 80% YoY and by 58% from the previous quarter
The ROS has plunged by 77% YoY and by 57% from the previous quarter

Dividends

What is BIIB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIIB.

Financial health

How did Biogen financials performed over time
The total assets is 144% more than the total liabilities
The company's quick ratio fell by 46% YoY
The current ratio has contracted by 28% YoY but it has grown by 4.3% from the previous quarter
Biogen's debt is 59% less than its equity
Biogen's debt has increased by 18% YoY but it has decreased by 7% from the previous quarter
The debt to equity has increased by 14% YoY but it has decreased by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.